
If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency disorder. The resubmission of the supplemental New Drug Application (sNDA) seeks approval for dosages…









